References - Chapter 4

1. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14(10):619-33.
http://www.ncbi.nlm.nih.gov/pubmed/5318831
2. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974 Nov 30;2(7892):1279-83.
http://www.ncbi.nlm.nih.gov/pubmed/4139522
3. Nerup J, Andersen OO, Bendixen G, Egeberg J, Poulsen JE. Anti-pancreatic cellular hypersensitivity in diabetes mellitus. Diabetes. 1971 Jun;20(6):424-7.
http://www.ncbi.nlm.nih.gov/pubmed/4592085
4. MacCuish AC, Jordan J, Campbell CJ, Duncan LJ, Irvine WJ. Cell-mediated immunity to human pancreas in diabetes mellitus. Diabetes. 1974 Aug;23(8):693-7.
http://www.ncbi.nlm.nih.gov/pubmed/4478993
5. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med. 1981;70(1):105-15.
http://www.ncbi.nlm.nih.gov/pubmed/7006384
6. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med. 1985;313(6):353-60.
http://www.ncbi.nlm.nih.gov/pubmed/3159965
7. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009 Feb;155(2):173-81.
http://www.ncbi.nlm.nih.gov/pubmed/19128359
8. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia. 2003 Mar;46(3):305-21.
http://www.ncbi.nlm.nih.gov/pubmed/12687328
9. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985 Aug;53(2):132-44.
http://www.ncbi.nlm.nih.gov/pubmed/3894793
10. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80-7.
http://www.ncbi.nlm.nih.gov/pubmed/6398950
11. Lampeter EF, Homberg M, Quabeck K, Schaefer UW, Wernet P, Bertrams J, et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet. 1993 May 15;341(8855):1243-4.
http://www.ncbi.nlm.nih.gov/pubmed/8098394
12. Van Vliet E, Roep BO, Meulenbroek L, Bruining GJ, De Vries RR. Human T cell clones with specificity for insulinoma cell antigens. Eur J Immunol. 1989;19(1):213-6.
http://www.ncbi.nlm.nih.gov/pubmed/2465903
13. Roep BO, Arden SD, de Vries RR, Hutton JC. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature. 1990;345(6276):632-4.
http://www.ncbi.nlm.nih.gov/pubmed/2190098
14. Roep BO, Kallan AA, Hazenbos WL, Bruining GJ, Bailyes EM, Arden SD, et al. T-cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes. Lancet. 1991;337(8755):1439-41.
http://www.ncbi.nlm.nih.gov/pubmed/1675318
15. Neophytou PI, Ozegbe P, Healey D, Quartey-Papafio R, Cooke A, Hutton JC. Development of a procedure for the direct cloning of T-cell epitopes using bacterial expression systems. J Immunol Methods. 1996 Sep 13;196(1):63-72.
http://www.ncbi.nlm.nih.gov/pubmed/8841444
16. Arden SD, Roep BO, Neophytou PI, Usac EF, Duinkerken G, de Vries RR, et al. Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient. J Clin Invest. 1996 Jan 15;97(2):551-61.
http://www.ncbi.nlm.nih.gov/pubmed/8567980
17. Kallan AA, Roep BO, Arden SD, Hutton JC, de Vries RR. Beta-cell reactive T-cell clones from type I diabetes patients are not beta cell specific and recognize multiple antigens. J Autoimmun. 1995 Dec;8(6):887-99.
http://www.ncbi.nlm.nih.gov/pubmed/8824713
18. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692-8.
http://www.ncbi.nlm.nih.gov/pubmed/12037148
19. Like AA, Butler L, Williams RM, Appel MC, Weringer EJ, Rossini AA. Spontaneous autoimmune diabetes mellitus in the BB rat. Diabetes. 1982;31(Suppl 1 Pt 2):7-13.
http://www.ncbi.nlm.nih.gov/pubmed/6761194
20. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980 Jan;29(1):1-13.
http://www.ncbi.nlm.nih.gov/pubmed/6995140
21. Makino S. Genetic analysis of IDDM in NOD mice. Exp Anim. 1998 Apr;47(2):suppl 107-9.
http://www.ncbi.nlm.nih.gov/pubmed/9606431
22. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med. 1999 Jun;5(6):601-4.
http://www.ncbi.nlm.nih.gov/pubmed/10371488
23. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 1997 Dec;7(6):727-38.
http://www.ncbi.nlm.nih.gov/pubmed/9430219
24. Hanninen A, Hamilton-Williams E, Kurts C. Development of new strategies to prevent type 1 diabetes: the role of animal models. Ann Med. 2003;35(8):546-63.
http://www.ncbi.nlm.nih.gov/pubmed/14708966
25. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005 Aug;23(2):115-26.
http://www.ncbi.nlm.nih.gov/pubmed/16111631
26. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol. 1993 Mar 15;150(6):2534-43.
http://www.ncbi.nlm.nih.gov/pubmed/8450229
27. Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. J Exp Med. 1993 Apr 1;177(4):1221-6.
http://www.ncbi.nlm.nih.gov/pubmed/8459217
28. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. J Immunol. 1988 Jun 1;140(11):3801-7.
http://www.ncbi.nlm.nih.gov/pubmed/2897395
29. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol. 1996 Jan 15;156(2):450-8.
http://www.ncbi.nlm.nih.gov/pubmed/8543793
30. Kreuwel HT, Biggs JA, Pilip IM, Pamer EG, Lo D, Sherman LA. Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice. J Immunol. 2001 Jul 15;167(2):1112-7.
http://www.ncbi.nlm.nih.gov/pubmed/11441123
31. Jansen A, van Hagen M, Drexhage HA. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet. 1995 Feb 25;345(8948):491-2.
http://www.ncbi.nlm.nih.gov/pubmed/7861877
32. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002 Jan;109(1):131-40.
http://www.ncbi.nlm.nih.gov/pubmed/11781358
33. Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, Mayr WR, et al. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol. 2003 Jan;221(1):15-26.
http://www.ncbi.nlm.nih.gov/pubmed/12742378
34. Lang J, Bellgrau D. A T-cell functional phenotype common among autoimmune-prone rodent strains. Scand J Immunol. 2002 Jun;55(6):546-59.
http://www.ncbi.nlm.nih.gov/pubmed/12028557
35. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004 Mar 1;172(5):2731-8.
http://www.ncbi.nlm.nih.gov/pubmed/14978070
36. Roep BO, Atkinson M. Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia. 2004 Oct;47(10):1650-6.
http://www.ncbi.nlm.nih.gov/pubmed/15490110
37. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol. 2004 Dec;4(12):989-97.
http://www.ncbi.nlm.nih.gov/pubmed/15573133
38. Leiter EH, von Herrath M. Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal. Diabetologia. 2004 Oct;47(10):1657-60.
http://www.ncbi.nlm.nih.gov/pubmed/15502929
39. Serreze DV, Chen YG. Of mice and men: use of animal models to identify possible interventions for the prevention of autoimmune type 1 diabetes in humans. Trends Immunol. 2005 Nov;26(11):603-7.
http://www.ncbi.nlm.nih.gov/pubmed/16140038
40. Kanazawa Y, Komeda K, Sato S, Mori S, Akanuma K, Takaku F. Non-obese-diabetic mice: immune mechanisms of pancreatic beta-cell destruction. Diabetologia. 1984 Jul;27 Suppl:113-5.
http://www.ncbi.nlm.nih.gov/pubmed/6383913
41. Miyazaki A, Hanafusa T, Yamada K, Miyagawa J, Fujino-Kurihara H, Nakajima H, et al. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin Exp Immunol. 1985 Jun;60(3):622-30.
http://www.ncbi.nlm.nih.gov/pubmed/3160515
42. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest. 1993 Nov;92(5):2313-22.
http://www.ncbi.nlm.nih.gov/pubmed/8227346
43. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994;91(1):123-7.
http://www.ncbi.nlm.nih.gov/pubmed/8278351
44. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol. 1997;158(6):2947-54.
http://www.ncbi.nlm.nih.gov/pubmed/9058834
45. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes. 1986;35(8):855-60.
http://www.ncbi.nlm.nih.gov/pubmed/3525284
46. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med. 1987;166(4):823-32.
http://www.ncbi.nlm.nih.gov/pubmed/3309126
47. Nagata M, Yoon JW. Studies on autoimmunity for T-cell-mediated beta-cell destruction. Distinct difference in beta-cell destruction between CD4+ and CD8+ T-cell clones derived from lymphocytes infiltrating the islets of NOD mice. Diabetes. 1992 Aug;41(8):998-1008.
http://www.ncbi.nlm.nih.gov/pubmed/1628775
48. Wong FS, Visintin I, Wen L, Flavell RA, Janeway CA, Jr. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med. 1996;183(1):67-76.
http://www.ncbi.nlm.nih.gov/pubmed/8551245
49. Bergman B, Haskins K. Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes. 1994;43(2):197-203.
http://www.ncbi.nlm.nih.gov/pubmed/8288043
50. Haskins K, Portas M, Bergman B, Lafferty K, Bradley B. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sci U S A. 1989;86(20):8000-4.
http://www.ncbi.nlm.nih.gov/pubmed/2510155
51. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell. 1993;74(6):1089-100.
http://www.ncbi.nlm.nih.gov/pubmed/8402882
52. Gonzalez A, Katz JD, Mattei MG, Kikutani H, Benoist C, Mathis D. Genetic control of diabetes progression. Immunity. 1997 Dec;7(6):873-83.
http://www.ncbi.nlm.nih.gov/pubmed/9430232
53. Andre-Schmutz I, Hindelang C, Benoist C, Mathis D. Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur J Immunol. 1999 Jan;29(1):245-55.
http://www.ncbi.nlm.nih.gov/pubmed/9933106
54. Kurrer MO, Pakala SV, Hanson HL, Katz JD. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci U S A. 1997;94(1):213-8.
http://www.ncbi.nlm.nih.gov/pubmed/8990188
55. Luhder F, Katz J, Benoist C, Mathis D. Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. J Exp Med. 1998 Feb 2;187(3):379-87.
http://www.ncbi.nlm.nih.gov/pubmed/9449718
56. Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes. 1994 Mar;43(3):505-9.
http://www.ncbi.nlm.nih.gov/pubmed/8314025
57. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol. 1993 Dec;23(12):3358-60.
http://www.ncbi.nlm.nih.gov/pubmed/8258349
58. Sumida T, Furukawa M, Sakamoto A, Namekawa T, Maeda T, Zijlstra M, et al. Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice. Int Immunol. 1994 Sep;6(9):1445-9.
http://www.ncbi.nlm.nih.gov/pubmed/7819154
59. Wicker LS, Leiter EH, Todd JA, Renjilian RJ, Peterson E, Fischer PA, et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes. 1994 Mar;43(3):500-4.
http://www.ncbi.nlm.nih.gov/pubmed/8314024
60. Hamilton-Williams EE, Serreze DV, Charlton B, Johnson EA, Marron MP, Mullbacher A, et al. Transgenic rescue implicates beta2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11533-8.
http://www.ncbi.nlm.nih.gov/pubmed/11572996
61. Perarnau B, Siegrist CA, Gillet A, Vincent C, Kimura S, Lemonnier FA. Beta 2-microglobulin restriction of antigen presentation. Nature. 1990 Aug 23;346(6286):751-4.
http://www.ncbi.nlm.nih.gov/pubmed/1697039
62. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A. 2003;100(18):10376-81.
http://www.ncbi.nlm.nih.gov/pubmed/12925730
63. Thebault-Baumont K, Dubois-Laforgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, et al. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest. 2003;111(6):851-7.
http://www.ncbi.nlm.nih.gov/pubmed/12639991
64. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005 May 12;435(7039):220-3.
http://www.ncbi.nlm.nih.gov/pubmed/15889095
65. Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetologia. 2004 Jan;47(1):149-50.
http://www.ncbi.nlm.nih.gov/pubmed/14614561
66. Kubosaki A, Gross S, Miura J, Saeki K, Zhu M, Nakamura S, et al. Targeted disruption of the IA-2ß gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of Diabetes in NOD mice. Diabetes. 2004;53:1684-91.
http://www.ncbi.nlm.nih.gov/pubmed/15220191
67. Kash SF, Condie BG, Baekkeskov S. Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Horm Metab Res. 1999;31(5):340-4.
http://www.ncbi.nlm.nih.gov/pubmed/10422732
68. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, et al. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest. 2007 Jul;117(7):1835-43.
http://www.ncbi.nlm.nih.gov/pubmed/17607359
69. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest. 2006 Dec;116(12):3258-65.
http://www.ncbi.nlm.nih.gov/pubmed/17143333
70. Krishnamurthy B, Mariana L, Gellert SA, Colman PG, Harrison LC, Lew AM, et al. Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J Immunol. 2008 Apr 1;180(7):4458-64.
http://www.ncbi.nlm.nih.gov/pubmed/18354167
71. Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA. Generation of T-cell receptor retrogenic mice. Nat Protoc. 2006;1(1):406-17.
http://www.ncbi.nlm.nih.gov/pubmed/17406263
72. Burton AR, Vincent E, Arnold PY, Lennon GP, Smeltzer M, Li CS, et al. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes. 2008 May;57(5):1321-30.
http://www.ncbi.nlm.nih.gov/pubmed/18299317
73. Adams TE, Alpert S, Hanahan D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature. 1987;325(6101):223-8.
http://www.ncbi.nlm.nih.gov/pubmed/3543686
74. Jolicoeur C, Hanahan D, Smith KM. T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6707-11.
http://www.ncbi.nlm.nih.gov/pubmed/8022837
75. Mathis D, Benoist C. Back to central tolerance. Immunity. 2004 May;20(5):509-16.
http://www.ncbi.nlm.nih.gov/pubmed/15142520
76. Forster I, Hirose R, Arbeit JM, Clausen BE, Hanahan D. Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity. 1995 Jun;2(6):573-85.
http://www.ncbi.nlm.nih.gov/pubmed/7796292
77. Heath WR, Allison J, Hoffmann MW, Schonrich G, Hammerling G, Arnold B, et al. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature. 1992;359(6395):547-9.
http://www.ncbi.nlm.nih.gov/pubmed/1406974
78. Heath WR, Karamalis F, Donoghue J, Miller JF. Autoimmunity caused by ignorant CD8+ T cells is transient and depends on avidity. J Immunol. 1995 Sep 1;155(5):2339-49.
http://www.ncbi.nlm.nih.gov/pubmed/7650369
79. Kurts C, Sutherland RM, Davey G, Li M, Lew AM, Blanas E, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12703-7.
http://www.ncbi.nlm.nih.gov/pubmed/10535986
80. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med. 1998 Jul 20;188(2):409-14.
http://www.ncbi.nlm.nih.gov/pubmed/9670054
81. Behrens GM, Li M, Davey GM, Allison J, Flavell RA, Carbone FR, et al. Helper requirements for generation of effector CTL to islet beta cell antigens. J Immunol. 2004 May 1;172(9):5420-6.
http://www.ncbi.nlm.nih.gov/pubmed/15100283
82. Kurts C, Heath WR, Carbone FR, Allison J, Miller JF, Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med. 1996 Sep 1;184(3):923-30.
http://www.ncbi.nlm.nih.gov/pubmed/9064352
83. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol. 2001 May 15;166(10):6099-103.
http://www.ncbi.nlm.nih.gov/pubmed/11342628
84. Nikolic-Zugic J, Bevan MJ. Role of self-peptides in positively selecting the T-cell repertoire. Nature. 1990 Mar 1;344(6261):65-7.
http://www.ncbi.nlm.nih.gov/pubmed/2304556
85. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med. 1997 Jul 21;186(2):239-45.
http://www.ncbi.nlm.nih.gov/pubmed/9221753
86. Kurts C, Heath WR, Kosaka H, Miller JF, Carbone FR. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med. 1998 Jul 20;188(2):415-20.
http://www.ncbi.nlm.nih.gov/pubmed/9670055
87. Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med. 1997 Dec 15;186(12):2057-62.
http://www.ncbi.nlm.nih.gov/pubmed/9396776
88. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol. 2002 Mar 1;168(5):2240-6.
http://www.ncbi.nlm.nih.gov/pubmed/11859111
89. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell. 1991 Apr 19;65(2):319-31.
http://www.ncbi.nlm.nih.gov/pubmed/1901765
90. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991 Apr 19;65(2):305-17.
http://www.ncbi.nlm.nih.gov/pubmed/1901764
91. Lee MS, von Herrath M, Reiser H, Oldstone MB, Sarvetnick N. Sensitization to self (virus) antigen by in situ expression of murine interferon-gamma. J Clin Invest. 1995 Feb;95(2):486-92.
http://www.ncbi.nlm.nih.gov/pubmed/7860730
92. von Herrath MG, Guerder S, Lewicki H, Flavell RA, Oldstone MB. Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity. 1995 Dec;3(6):727-38.
http://www.ncbi.nlm.nih.gov/pubmed/8777718
93. von Herrath MG, Dockter J, Oldstone MB. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity. 1994 Jun;1(3):231-42.
http://www.ncbi.nlm.nih.gov/pubmed/7889411
94. Slifka MK, Blattman JN, Sourdive DJ, Liu F, Huffman DL, Wolfe T, et al. Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J Immunol. 2003 Feb 1;170(3):1231-9.
http://www.ncbi.nlm.nih.gov/pubmed/12538681
95. Sevilla N, Homann D, von Herrath M, Rodriguez F, Harkins S, Whitton JL, et al. Virus-induced diabetes in a transgenic model: role of cross-reacting viruses and quantitation of effector T cells needed to cause disease. J Virol. 2000 Apr;74(7):3284-92.
http://www.ncbi.nlm.nih.gov/pubmed/10708445
96. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med. 2005 Feb;11(2):138-45.
http://www.ncbi.nlm.nih.gov/pubmed/15654326
97. von Herrath MG, Allison J, Miller JF, Oldstone MB. Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in beta cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response. J Clin Invest. 1995 Feb;95(2):477-85.
http://www.ncbi.nlm.nih.gov/pubmed/7860729
98. Rhode A, Pauza ME, Barral AM, Rodrigo E, Oldstone MB, von Herrath MG, et al. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol. 2005 Sep 15;175(6):3516-24.
http://www.ncbi.nlm.nih.gov/pubmed/16148094
99. von Herrath M, Holz A. Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM. J Autoimmun. 1997 Jun;10(3):231-8.
http://www.ncbi.nlm.nih.gov/pubmed/9218748
100. Christen U, von Herrath MG. Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol Immunol. 2004 Feb;40(14-15):1113-20.
http://www.ncbi.nlm.nih.gov/pubmed/15036917
101. Filippi C, von Herrath M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol. 2005 Feb;233(2):125-32.
http://www.ncbi.nlm.nih.gov/pubmed/15963965
102. Lo D, Freedman J, Hesse S, Palmiter RD, Brinster RL, Sherman LA. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol. 1992 Apr;22(4):1013-22.
http://www.ncbi.nlm.nih.gov/pubmed/1348026
103. Morgan DJ, Kreuwel HT, Sherman LA. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol. 1999 Jul 15;163(2):723-7.
http://www.ncbi.nlm.nih.gov/pubmed/10395663
104. Piaggio E, Hartemann-Heurtier A, Cabarrocas J, Desbois S, Mars LT, Zappulla JP, et al. Maintaining or breaking CD8+ T-cell tolerance to beta islet cell antigens: lessons from transgenic mouse models. J Autoimmun. 2004 Mar;22(2):115-20.
http://www.ncbi.nlm.nih.gov/pubmed/14987739
105. Morgan DJ, Kurts C, Kreuwel HT, Holst KL, Heath WR, Sherman LA. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3854-8.
http://www.ncbi.nlm.nih.gov/pubmed/10097127
106. Mintern JD, Sutherland RM, Lew AM, Shortman K, Carbone FR, Heath WR. Constitutive, but not inflammatory, cross-presentation is disabled in the pancreas of young mice. Eur J Immunol. 2002 Apr;32(4):1044-51.
http://www.ncbi.nlm.nih.gov/pubmed/11920571
107. Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, et al. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol. 1996 Aug 1;157(3):978-83.
http://www.ncbi.nlm.nih.gov/pubmed/8757600
108. Degermann S, Reilly C, Scott B, Ogata L, von Boehmer H, Lo D. On the various manifestations of spontaneous autoimmune diabetes in rodent models. Eur J Immunol. 1994 Dec;24(12):3155-60.
http://www.ncbi.nlm.nih.gov/pubmed/7528672
109. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, et al. A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity. 1994;1(1):73-83.
http://www.ncbi.nlm.nih.gov/pubmed/7889402
110. Roman LM, Simons LF, Hammer RE, Sambrook JF, Gething MJ. The expression of influenza virus hemagglutinin in the pancreatic beta cells of transgenic mice results in autoimmune diabetes. Cell. 1990 May 4;61(3):383-96.
http://www.ncbi.nlm.nih.gov/pubmed/2185889
111. Abiru N, Maniatis AK, Yu L, Miao D, Moriyama H, Wegmann D, et al. Peptide and major histocompatibility complex-specific breaking of humoral tolerance to native insulin with the B9-23 peptide in diabetes-prone and normal mice. Diabetes. 2001 Jun;50(6):1274-81.
http://www.ncbi.nlm.nih.gov/pubmed/11375327
112. Moriyama H, Wen L, Abiru N, Liu E, Yu L, Miao D, et al. Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci U S A. 2002;99(8):5539-44.
http://www.ncbi.nlm.nih.gov/pubmed/11943868
113. Havari E, Lennon-Dumenil AM, Klein L, Neely D, Taylor JA, McInerney MF, et al. Expression of the B7.1 costimulatory molecule on pancreatic beta cells abrogates the requirement for CD4 T cells in the development of type 1 diabetes. J Immunol. 2004 Jul 15;173(2):787-96.
http://www.ncbi.nlm.nih.gov/pubmed/15240665
114. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library [see comments]. Nat Med. 1999;5(9):1026-31.
http://www.ncbi.nlm.nih.gov/pubmed/10470079
115. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science. 1993 Jun 25;260(5116):1942-6.
http://www.ncbi.nlm.nih.gov/pubmed/8100367
116. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity. 2004 May;20(5):539-50.
http://www.ncbi.nlm.nih.gov/pubmed/15142523
117. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996 Jun 28;272(5270):1947-50.
http://www.ncbi.nlm.nih.gov/pubmed/8658169
118. Vezys V, Lefrancois L. Cutting edge: inflammatory signals drive organ-specific autoimmunity to normally cross-tolerizing endogenous antigen. J Immunol. 2002 Dec 15;169(12):6677-80.
http://www.ncbi.nlm.nih.gov/pubmed/12471097
119. Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol. 2004 Mar 1;172(5):3173-80.
http://www.ncbi.nlm.nih.gov/pubmed/14978124
120. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med. 1998 Jul;4(7):781-5.
http://www.ncbi.nlm.nih.gov/pubmed/9662368
121. Wong S, Guerder S, Visintin I, Reich EP, Swenson KE, Flavell RA, et al. Expression of the co-stimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse. Diabetes. 1995 Mar;44(3):326-9.
http://www.ncbi.nlm.nih.gov/pubmed/7533734
122. Guerder S, Picarella DE, Linsley PS, Flavell RA. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5138-42.
http://www.ncbi.nlm.nih.gov/pubmed/7515187
123. Karges W, Pechhold K, Al Dahouk S, Riegger I, Rief M, Wissmann A, et al. Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes. 2002 Nov;51(11):3237-44.
http://www.ncbi.nlm.nih.gov/pubmed/12401715
124. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2260-3.
http://www.ncbi.nlm.nih.gov/pubmed/8637860
125. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol. 1995;13:179-200.
http://www.ncbi.nlm.nih.gov/pubmed/7612220
126. Robles DT, Eisenbarth GS, Dailey NJ, Peterson LB, Wicker LS. Insulin autoantibodies are associated with islet inflammation but not always related to diabetes progression in NOD congenic mice. Diabetes. 2003 Mar;52(3):882-6.
http://www.ncbi.nlm.nih.gov/pubmed/12606534
127. Maynard J, Petersson K, Wilson DH, Adams EJ, Blondelle SE, Boulanger MJ, et al. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity. 2005 Jan;22(1):81-92.
http://www.ncbi.nlm.nih.gov/pubmed/15664161
128. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. Embo J. 2005 Sep 7;24(17):2968-79.
http://www.ncbi.nlm.nih.gov/pubmed/16079912
129. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol. 2005 May;6(5):490-6.
http://www.ncbi.nlm.nih.gov/pubmed/15821740
130. Nicholson MJ, Hahn M, Wucherpfennig KW. Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity. 2005 Oct;23(4):351-60.
http://www.ncbi.nlm.nih.gov/pubmed/16226501
131. Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok WW, et al. Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood. 2005 Oct 15;106(8):2798-805.
http://www.ncbi.nlm.nih.gov/pubmed/16030184
132. Liston A, Lesage S, Gray DH, O'Reilly LA, Strasser A, Fahrer AM, et al. Generalized resistance to thymic deletion in the NOD mouse; a polygenic trait characterized by defective induction of Bim. Immunity. 2004 Dec;21(6):817-30.
http://www.ncbi.nlm.nih.gov/pubmed/15589170
133. Peterson LD, van der Keur M, de Vries RR, Roep BO. Autoreactive and immunoregulatory T-cell subsets in insulin-dependent diabetes mellitus. Diabetologia. 1999;42(4):443-9.
http://www.ncbi.nlm.nih.gov/pubmed/10230648
134. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest. 2004 Feb;113(3):451-63.
http://www.ncbi.nlm.nih.gov/pubmed/14755342
135. Linn T, Strate C, Federlin K, Papaccio G. Intercellular adhesion molecule-1 (ICAM-1) expression in the islets of the non-obese diabetic and low-dose streptozocin-treated mouse. Histochemistry. 1994;102(4):317-21.
http://www.ncbi.nlm.nih.gov/pubmed/7843994
136. Hanninen A, Taylor C, Streeter PR, Stark LS, Sarte JM, Shizuru JA, et al. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest. 1993;92(5):2509-15.
http://www.ncbi.nlm.nih.gov/pubmed/7693764
137. Faveeuw C, Gagnerault MC, Lepault F. Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice. J Immunol. 1994;152(12):5969-78.
http://www.ncbi.nlm.nih.gov/pubmed/8207221
138. Baron JL, Reich EP, Visintin I, Janeway CA, Jr. The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest. 1994;93(4):1700-8.
http://www.ncbi.nlm.nih.gov/pubmed/7512990
139. Hasegawa Y, Yokono K, Taki T, Amano K, Tominaga Y, Yoneda R, et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol. 1994;6(6):831-8.
http://www.ncbi.nlm.nih.gov/pubmed/7916204
140. Yang XD, Karin N, Tisch R, Steinman L, McDevitt HO. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci U S A. 1993;90(22):10494-8.
http://www.ncbi.nlm.nih.gov/pubmed/7504266
141. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol. 2001 Feb;2(2):123-8.
http://www.ncbi.nlm.nih.gov/pubmed/11175804
142. Greening JE, Tree TI, Kotowicz KT, van Halteren AG, Roep BO, Klein NJ, et al. Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes. 2003 Mar;52(3):717-25.
http://www.ncbi.nlm.nih.gov/pubmed/12606513
143. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med. 2003 Mar 3;197(5):643-56.
http://www.ncbi.nlm.nih.gov/pubmed/12615905
144. Turley SJ, Lee JW, Dutton-Swain N, Mathis D, Benoist C. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17729-33.
http://www.ncbi.nlm.nih.gov/pubmed/16317068
145. Rosmalen JG, Leenen PJ, Pelegri C, Drexhage HA, Homo-Delarche F. Islet abnormalities in the pathogenesis of autoimmune diabetes. Trends Endocrinol Metab. 2002 Jul;13(5):209-14.
http://www.ncbi.nlm.nih.gov/pubmed/12185667
146. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997 Aug 8;277(5327):818-21.
http://www.ncbi.nlm.nih.gov/pubmed/9242611
147. Horwitz MS, Ilic A, Fine C, Rodriguez E, Sarvetnick N. Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J Clin Invest. 2002 Jan;109(1):79-87.
http://www.ncbi.nlm.nih.gov/pubmed/11781353
148. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes. 2000 Jan;49(1):1-7.
http://www.ncbi.nlm.nih.gov/pubmed/10615942
149. Hugues S, Mougneau E, Ferlin W, Jeske D, Hofman P, Homann D, et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity. 2002 Feb;16(2):169-81.
http://www.ncbi.nlm.nih.gov/pubmed/11869679
150. Herold KC. Achieving antigen-specific immune regulation. J Clin Invest. 2004 Feb;113(3):346-9.
http://www.ncbi.nlm.nih.gov/pubmed/14755329
151. Hyoty H, Taylor KW. The role of viruses in human diabetes. Diabetologia. 2002 Oct;45(10):1353-61.
http://www.ncbi.nlm.nih.gov/pubmed/12378375
152. O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes. 2002 Aug;51(8):2481-8.
http://www.ncbi.nlm.nih.gov/pubmed/12145161
153. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Erlich HA, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. Jama. 2003 Oct 1;290(13):1713-20.
http://www.ncbi.nlm.nih.gov/pubmed/14519705
154. Winer S, Tsui H, Lau A, Song A, Li X, Cheung RK, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med. 2003 Feb;9(2):198-205.
http://www.ncbi.nlm.nih.gov/pubmed/12539039
155. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med. 2002 Aug 5;196(3):369-77.
http://www.ncbi.nlm.nih.gov/pubmed/12163565
156. Jaakkola I, Jalkanen S, Hanninen A. Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. Eur J Immunol. 2003 Dec;33(12):3255-64.
http://www.ncbi.nlm.nih.gov/pubmed/14635033
157. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med. 2005 Nov 21;202(10):1387-97.
http://www.ncbi.nlm.nih.gov/pubmed/16301745
158. Hanninen A, Jaakkola I, Jalkanen S. Mucosal addressin is required for the development of diabetes in nonobese diabetic mice. J Immunol. 1998 Jun 15;160(12):6018-25.
http://www.ncbi.nlm.nih.gov/pubmed/9637517
159. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med. 1999 Jan 18;189(2):331-9.
http://www.ncbi.nlm.nih.gov/pubmed/9892615
160. Haskins K, Portas M, Bradley B, Wegmann D, Lafferty K. T-lymphocyte clone specific for pancreatic islet antigen. Diabetes. 1988 Oct;37(10):1444-8.
http://www.ncbi.nlm.nih.gov/pubmed/2458291
161. Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes. 2000 Aug;49(8):1325-33.
http://www.ncbi.nlm.nih.gov/pubmed/10923633
162. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. Jama. 2003 Oct 1;290(13):1721-8.
http://www.ncbi.nlm.nih.gov/pubmed/14519706
163. Larger E, Becourt C, Bach JF, Boitard C. Pancreatic islet beta cells drive T cell-immune responses in the nonobese diabetic mouse model. J Exp Med. 1995 May 1;181(5):1635-42.
http://www.ncbi.nlm.nih.gov/pubmed/7722443
164. Baker FJ, Lee M, Chien YH, Davis MM. Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9374-9.
http://www.ncbi.nlm.nih.gov/pubmed/12082183
165. Yang Y, Charlton B, Shimada A, Dal Canto R, Fathman CG. Monoclonal T cells identified in early NOD islet infiltrates. Immunity. 1996 Feb;4(2):189-94.
http://www.ncbi.nlm.nih.gov/pubmed/8624809
166. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest. 2001 Nov;108(9):1247-52.
http://www.ncbi.nlm.nih.gov/pubmed/11696564
167. Tian J, Gregori S, Adorini L, Kaufman DL. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol. 2001 Jun 15;166(12):7144-50.
http://www.ncbi.nlm.nih.gov/pubmed/11390460
168. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature. 2000 Aug 17;406(6797):739-42.
http://www.ncbi.nlm.nih.gov/pubmed/10963600
169. Homann D, Holz A, Bot A, Coon B, Wolfe T, Petersen J, et al. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity. 1999 Oct;11(4):463-72.
http://www.ncbi.nlm.nih.gov/pubmed/10549628
170. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004 Jun 7;199(11):1455-65.
http://www.ncbi.nlm.nih.gov/pubmed/15184499
171. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004 Jun 7;199(11):1467-77.
http://www.ncbi.nlm.nih.gov/pubmed/15184500
172. Castano L, Russo E, Zhou L, Lipes MA, Eisenbarth GS. Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with type I diabetes. J Clin Endocrinol Metab. 1991 Dec;73(6):1197-201.
http://www.ncbi.nlm.nih.gov/pubmed/1955501
173. Martin S, Lampasona V, Dosch M, Pietropaolo M. Islet cell autoantigen 69 antibodies in IDDM. Diabetologia. 1996 Jun;39(6):747.
http://www.ncbi.nlm.nih.gov/pubmed/8781774
174. Buschard K, Josefsen K, Horn T, Fredman P. Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet. 1993 Oct 2;342(8875):840.
http://www.ncbi.nlm.nih.gov/pubmed/8104274
175. Eisenbarth GS, Moriyama H, Robles DT, Liu E, Yu L, Babu S, et al. Insulin autoimmunity: prediction/precipitation/prevention type 1A diabetes. Autoimmun Rev. 2002 May;1(3):139-45.
http://www.ncbi.nlm.nih.gov/pubmed/12849007
176. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 1998 Oct 15;161(8):3912-8.
http://www.ncbi.nlm.nih.gov/pubmed/9780157
177. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med. 2001 Oct 4;345(14):1036-40.
http://www.ncbi.nlm.nih.gov/pubmed/11586956
178. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes. 2008 Oct;57(10):2693-7.
http://www.ncbi.nlm.nih.gov/pubmed/18591387
179. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1701-6.
http://www.ncbi.nlm.nih.gov/pubmed/10677521
180. Bowie L, Tite J, Cooke A. Generation and maintenance of autoantigen-specific CD8(+) T cell clones isolated from NOD mice. J Immunol Methods. 1999 Aug 31;228(1-2):87-95.
http://www.ncbi.nlm.nih.gov/pubmed/10556546
181. Nagata M, Santamaria P, Kawamura T, Utsugi T, Yoon JW. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J Immunol. 1994 Feb 15;152(4):2042-50.
http://www.ncbi.nlm.nih.gov/pubmed/7907110
182. Wegmann DR, Shehadeh N, Lafferty KJ, Norbury-Glaser M, Gill RG, Daniel D. Establishment of islet-specific T-cell lines and clones from islet isografts placed in spontaneously diabetic NOD mice. J Autoimmun. 1993 Oct;6(5):517-27.
http://www.ncbi.nlm.nih.gov/pubmed/7902094
183. Tree TI, O'Byrne D, Tremble JM, MacFarlane WM, Haskins K, James RF, et al. Evidence for recognition of novel islet T cell antigens by granule-specific T cell lines from new onset type 1 diabetic patients. Clin Exp Immunol. 2000 Jul;121(1):100-5.
http://www.ncbi.nlm.nih.gov/pubmed/10886245
184. Malarkannan S, Horng T, Shih PP, Schwab S, Shastri N. Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism. Immunity. 1999 Jun;10(6):681-90.
http://www.ncbi.nlm.nih.gov/pubmed/10403643
185. Engelhard VH. Creating new peptide antigens by slicing and splicing proteins. Nat Immunol. 2004 Feb;5(2):128-9.
http://www.ncbi.nlm.nih.gov/pubmed/14749782
186. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the {beta} cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8384-8.
http://www.ncbi.nlm.nih.gov/pubmed/12815107
187. Lieberman SM, Takaki T, Han B, Santamaria P, Serreze DV, DiLorenzo TP. Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol. 2004 Dec 1;173(11):6727-34.
http://www.ncbi.nlm.nih.gov/pubmed/15557165
188. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol. 1994 Aug;24(8):1853-7.
http://www.ncbi.nlm.nih.gov/pubmed/8056042
189. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol. 1995;25(4):1056-62.
http://www.ncbi.nlm.nih.gov/pubmed/7537670
190. Halbout P, Briand JP, Becourt C, Muller S, Boitard C. T cell response to preproinsulin I and II in the nonobese diabetic mouse. J Immunol. 2002 Sep 1;169(5):2436-43.
http://www.ncbi.nlm.nih.gov/pubmed/12193712
191. Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, Eisenbarth GS, et al. Evidence that a peptide spanning the B-C junction of proinsulin is an early Autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol. 2001 Nov 1;167(9):4926-35.
http://www.ncbi.nlm.nih.gov/pubmed/11673498
192. Congia M, Patel S, Cope AP, De Virgiliis S, Sonderstrup G. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3833-8.
http://www.ncbi.nlm.nih.gov/pubmed/9520453
193. Semana G, Gausling R, Jackson RA, Hafler DA. T cell autoreactivity to proinsulin epitopes in diabetic patients and healthy subjects. J Autoimmun. 1999 Jun;12(4):259-67.
http://www.ncbi.nlm.nih.gov/pubmed/10330297
194. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest. 2001 Jan;107(2):173-80.
http://www.ncbi.nlm.nih.gov/pubmed/11160133
195. Durinovic-Bello I, Boehm BO, Ziegler AG. Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity. J Autoimmun. 2002 Feb;18(1):55-66.
http://www.ncbi.nlm.nih.gov/pubmed/11869047
196. Mannering SI, Morris JS, Stone NL, Jensen KP, PM VANE, Harrison LC. CD4+ T cell proliferation in response to GAD and proinsulin in healthy, pre-diabetic, and diabetic donors. Ann N Y Acad Sci. 2004 Dec;1037:16-21.
http://www.ncbi.nlm.nih.gov/pubmed/15699488
197. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 2005 May 12;435(7039):224-8.
http://www.ncbi.nlm.nih.gov/pubmed/15889096
198. Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, Jensen KP, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med. 2005 Nov 7;202(9):1191-7.
http://www.ncbi.nlm.nih.gov/pubmed/16260488
199. Toma A, Haddouk S, Briand JP, Camoin L, Gahery H, Connan F, et al. Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10581-6.
http://www.ncbi.nlm.nih.gov/pubmed/16030147
200. Hutchings P, Cooke A. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun. 1998;11(2):127-30.
http://www.ncbi.nlm.nih.gov/pubmed/9650091
201. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med. 1996;184(6):2167-74.
http://www.ncbi.nlm.nih.gov/pubmed/8976172
202. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A. 1996;93(2):956-60.
http://www.ncbi.nlm.nih.gov/pubmed/8570667
203. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, Adorini L, et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest. 2003 May;111(9):1365-71.
http://www.ncbi.nlm.nih.gov/pubmed/12727928
204. Zekzer D, Wong FS, Wen L, Altieri M, Gurlo T, von Grafenstein H, et al. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes. 1997;46(7):1124-32.
http://www.ncbi.nlm.nih.gov/pubmed/9200646
205. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia. 2000 Aug;43(8):1000-4.
http://www.ncbi.nlm.nih.gov/pubmed/10990077
206. Wilson DM. Progress in the treatment of childhood diabetes mellitus and obesity. J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:745-9.
http://www.ncbi.nlm.nih.gov/pubmed/12092689
207. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005 May;28(5):1068-76.
http://www.ncbi.nlm.nih.gov/pubmed/15855569
208. Lernmark A, Agardh CD. Immunomodulation with human recombinant autoantigens. Trends Immunol. 2005 Nov;26(11):608-12.
http://www.ncbi.nlm.nih.gov/pubmed/16153889
209. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002;51(7):2126-34.
http://www.ncbi.nlm.nih.gov/pubmed/12086942
210. Pugliese A. Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword. J Clin Invest. 2003 May;111(9):1280-2.
http://www.ncbi.nlm.nih.gov/pubmed/12727917
211. Ohneda K, Ee H, German M. Regulation of insulin gene transcription. Semin Cell Dev Biol. 2000 Aug;11(4):227-33.
http://www.ncbi.nlm.nih.gov/pubmed/10966856
212. Heath VL, Moore NC, Parnell SM, Mason DW. Intrathymic expression of genes involved in organ specific autoimmune disease. J Autoimmun. 1998;11(4):309-18.
http://www.ncbi.nlm.nih.gov/pubmed/9776708
213. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo M, et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest. 2001 Mar;107(5):555-64.
http://www.ncbi.nlm.nih.gov/pubmed/11238556
214. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15(3):289-92.
http://www.ncbi.nlm.nih.gov/pubmed/9054944
215. Throsby M, Homo-Delarche F, Chevenne D, Goya R, Dardenne M, Pleau JM. Pancreatic hormone expression in the murine thymus: localization in dendritic cells and macrophages. Endocrinology. 1998;139(5):2399-406.
http://www.ncbi.nlm.nih.gov/pubmed/9564851
216. Sospedra M, Ferrer-Francesch X, Dominguez O, Juan M, Foz-Sala M, Pujol-Borrell R. Transcription of a broad range of self-antigens in human thymus suggests a role for central mechanisms in tolerance toward peripheral antigens. J Immunol. 1998;161(11):5918-29.
http://www.ncbi.nlm.nih.gov/pubmed/9834072
217. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002 Nov 15;298(5597):1395-401.
http://www.ncbi.nlm.nih.gov/pubmed/12376594
218. Pugliese A. Central and peripheral autoantigen presentation in immune tolerance. Immunology. 2004 Feb;111(2):138-46.
http://www.ncbi.nlm.nih.gov/pubmed/15027898
219. Pugliese A, Zeller M, Fernandez A, Jr., Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997;15(3):293-7.
http://www.ncbi.nlm.nih.gov/pubmed/9054945
220. Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity. 2001 Sep;15(3):387-95.
http://www.ncbi.nlm.nih.gov/pubmed/11567629
221. Chentoufi AA, Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes. 2002;51(5):1383-90.
http://www.ncbi.nlm.nih.gov/pubmed/11978634
222. French MB, Allison J, Cram DS, Thomas HE, Dempsey-Collier M, Silva A, et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes. 1997 Jan;46(1):34-9.
http://www.ncbi.nlm.nih.gov/pubmed/8971078
223. Pugliese A, Diez J. Lymphoid organs contain diverse cells expressing self-molecules. Nat Immunol. 2002 Apr;3(4):335-6; author reply 6.
http://www.ncbi.nlm.nih.gov/pubmed/11919571
224. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004 Jan 19;199(2):155-66.
http://www.ncbi.nlm.nih.gov/pubmed/14734521
225. Chentoufi AA, Palumbo M, Polychronakos C. Proinsulin expression by Hassall's corpuscles in the mouse thymus. Diabetes. 2004 Feb;53(2):354-9.
http://www.ncbi.nlm.nih.gov/pubmed/14747285
226. Watanabe N, Wang YH, Lee HK, Ito T, Cao W, Liu YJ. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature. 2005 Aug 25;436(7054):1181-5.
http://www.ncbi.nlm.nih.gov/pubmed/16121185
227. Jaeckel E, Lipes MA, Von Boehmer H. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol. 2004 Sep 19.
http://www.ncbi.nlm.nih.gov/pubmed/15378058
228. Kojima H, Fujimiya M, Matsumura K, Nakahara T, Hara M, Chan L. Extrapancreatic insulin-producing cells in multiple organs in diabetes. Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2458-63.
http://www.ncbi.nlm.nih.gov/pubmed/14983031
229. Kobayashi M, Jasinski J, Liu E, Li M, Miao D, Zhang L, et al. Conserved T cell receptor alpha-chain induces insulin autoantibodies. Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10090-4.
http://www.ncbi.nlm.nih.gov/pubmed/18626021
230. Homann D, Eisenbarth GS. An immunologic homunculus for type 1 diabetes. J Clin Invest. 2006 May;116(5):1212-5.
http://www.ncbi.nlm.nih.gov/pubmed/16670763
231. Skowera A, Ellis RJ, Varela-Calvino R, Arif S, Huang GC, Van-Krinks C, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest. 2008 Oct;118(10):3390-402.
http://www.ncbi.nlm.nih.gov/pubmed/18802479
232. Durinovic-Bello I, Rosinger S, Olson JA, Congia M, Ahmad RC, Rickert M, et al. DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11683-8.
http://www.ncbi.nlm.nih.gov/pubmed/16868084
233. Lernmark A. Glutamic acid decarboxylase--gene to antigen to disease. J Intern Med. 1996 Nov;240(5):259-77.
http://www.ncbi.nlm.nih.gov/pubmed/8946809
234. Kim J, Richter W, Aanstoot HJ, Shi Y, Fu Q, Rajotte R, et al. Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes. 1993;42(12):1799-808.
http://www.ncbi.nlm.nih.gov/pubmed/8243826
235. Velloso LA, Eizirik DL, Karlsson FA, Kampe O. Absence of autoantibodies against glutamate decarboxylase (GAD) in the non-obese diabetic (NOD) mouse and low expression of the enzyme in mouse islets. Clin Exp Immunol. 1994 Apr;96(1):129-37.
http://www.ncbi.nlm.nih.gov/pubmed/8149657
236. Bieg S, Seissler J, Herberg L, Northemann W, Scherbaum WA. GAD65 is recognized by T-cells, but not by antibodies from NOD-mice. Autoimmunity. 1994;17(3):189-94.
http://www.ncbi.nlm.nih.gov/pubmed/7948603
237. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes [see comments]. Nature. 1993;366(6450):69-72.
http://www.ncbi.nlm.nih.gov/pubmed/7694152
238. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice [see comments]. Nature. 1993;366(6450):72-5.
http://www.ncbi.nlm.nih.gov/pubmed/8232539
239. Quinn A, McInerney B, Reich EP, Kim O, Jensen KP, Sercarz EE. Regulatory and effector CD4 T cells in nonobese diabetic mice recognize overlapping determinants on glutamic acid decarboxylase and use distinct V beta genes. J Immunol. 2001 Mar 1;166(5):2982-91.
http://www.ncbi.nlm.nih.gov/pubmed/11207247
240. Zechel MA, Elliott JF, Atkinson MA, Singh B. Characterization of novel T-cell epitopes on 65 kDa and 67 kDa glutamic acid decarboxylase relevant in autoimmune responses in NOD mice. J Autoimmun. 1998 Feb;11(1):83-95.
http://www.ncbi.nlm.nih.gov/pubmed/9480726
241. Chao CC, McDevitt HO. Identification of immunogenic epitopes of GAD 65 presented by Ag7 in non-obese diabetic mice. Immunogenetics. 1997;46(1):29-34.
http://www.ncbi.nlm.nih.gov/pubmed/9148785
242. Videbaek N, Harach S, Phillips J, Hutchings P, Ozegbe P, Michelsen BK, et al. An islet-homing NOD CD8+ cytotoxic T cell clone recognizes GAD65 and causes insulitis. J Autoimmun. 2003 Mar;20(2):97-109.
http://www.ncbi.nlm.nih.gov/pubmed/12657523
243. Atkinson MA, Kaufman DL, Campbell L, Gibbs KA, Shah SC, Bu DF, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet. 1992;339(8791):458-9.
http://www.ncbi.nlm.nih.gov/pubmed/1346821
244. Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun. 2005 Dec;25(4):303-11.
http://www.ncbi.nlm.nih.gov/pubmed/16249070
245. Ott PA, Herzog BA, Quast S, Hofstetter HH, Boehm BO, Tary-Lehmann M, et al. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin Immunol. 2005 Apr;115(1):102-14.
http://www.ncbi.nlm.nih.gov/pubmed/15870028
246. Jaume JC, Parry SL, Madec AM, Sonderstrup G, Baekkeskov S. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol. 2002 Jul 15;169(2):665-72.
http://www.ncbi.nlm.nih.gov/pubmed/12097368
247. Reijonen H, Daniels TL, Lernmark A, Nepom GT. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes. 2000 Oct;49(10):1621-6.
http://www.ncbi.nlm.nih.gov/pubmed/11016444
248. Liu J, Purdy LE, Rabinovitch S, Jevnikar AM, Elliott JF. Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Diabetes. 1999 Mar;48(3):469-77.
http://www.ncbi.nlm.nih.gov/pubmed/10078545
249. Nepom GT, Lippolis JD, White FM, Masewicz S, Marto JA, Herman A, et al. Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1763-8.
http://www.ncbi.nlm.nih.gov/pubmed/11172025
250. Ou D, Mitchell LA, Metzger DL, Gillam S, Tingle AJ. Cross-reactive rubella virus and glutamic acid decarboxylase (65 and 67) protein determinants recognised by T cells of patients with type I diabetes mellitus [In Process Citation]. Diabetologia. 2000;43(6):750-62.
http://www.ncbi.nlm.nih.gov/pubmed/10907121
251. Lohmann T, Leslie RD, Londei M. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. J Autoimmun. 1996 Jun;9(3):385-9.
http://www.ncbi.nlm.nih.gov/pubmed/8816975
252. Schloot NC, Roep BO, Wegmann DR, Yu L, Wang TB, Eisenbarth GS. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Diabetologia. 1997 Mar;40(3):332-8.
http://www.ncbi.nlm.nih.gov/pubmed/9084973
253. Endl J, Otto H, Jung G, Dreisbusch B, Donie F, Stahl P, et al. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest. 1997 May 15;99(10):2405-15.
http://www.ncbi.nlm.nih.gov/pubmed/9153283
254. Bach JM, Otto H, Nepom GT, Jung G, Cohen H, Timsit J, et al. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J Autoimmun. 1997 Aug;10(4):375-86.
http://www.ncbi.nlm.nih.gov/pubmed/9237801
255. Boyton RJ, Lohmann T, Londei M, Kalbacher H, Halder T, Frater AJ, et al. Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Int Immunol. 1998 Dec;10(12):1765-76.
http://www.ncbi.nlm.nih.gov/pubmed/9885897
256. Oling V, Marttila J, Ilonen J, Kwok WW, Nepom G, Knip M, et al. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun. 2005 Nov;25(3):235-43.
http://www.ncbi.nlm.nih.gov/pubmed/16263242
257. Hiemstra HS, Schloot NC, van Veelen PA, Willemen SJ, Franken KL, van Rood JJ, et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3988-91.
http://www.ncbi.nlm.nih.gov/pubmed/11274421
258. Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet. 1988 Jul 2;2(8601):1-4.
http://www.ncbi.nlm.nih.gov/pubmed/2898620
259. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest. 1994 Nov;94(5):2125-9.
http://www.ncbi.nlm.nih.gov/pubmed/7962558
260. Rudy G, Stone N, Harrison LC, Colman PG, McNair P, Brusic V, et al. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol Med. 1995 Sep;1(6):625-33.
http://www.ncbi.nlm.nih.gov/pubmed/8529129
261. Schloot NC, Willemen SJ, Duinkerken G, Drijfhout JW, de Vries RR, Roep BO. Molecular mimicry in type 1 diabetes mellitus revisited: T-cell clones to GAD65 peptides with sequence homology to Coxsackie or proinsulin peptides do not crossreact with homologous counterpart. Hum Immunol. 2001 Apr;62(4):299-309.
http://www.ncbi.nlm.nih.gov/pubmed/11295462
262. Panina-Bordignon P, Lang R, van Endert PM, Benazzi E, Felix AM, Pastore RM, et al. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med. 1995;181(5):1923-7.
http://www.ncbi.nlm.nih.gov/pubmed/7722468
263. Nepom G, Quinn A, Sercarz E, Wilson DB. How important is GAD in the etiology of spontaneous disease in human and murine type 1 diabetes? J Autoimmun. 2003 May;20(3):193-4.
http://www.ncbi.nlm.nih.gov/pubmed/12753801
264. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells [see comments]. Science. 1999;284(5417):1183-7.
http://www.ncbi.nlm.nih.gov/pubmed/10325232
265. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med. 2003 Jun 16;197(12):1635-44.
http://www.ncbi.nlm.nih.gov/pubmed/12796471
266. Yoon JW, Lim HW, Hirasawa K, Sherwin RS, Jun HS. Control of autoimmune diabetes. Science. 2000;287:191a.
http://www.ncbi.nlm.nih.gov/pubmed/10325232
267. Tian J, Kaufman DL. Control of autoimmune diabetes. Science. 2000;287:191a.
http://www.sciencemag.org/cgi/content/full/287/5451/191a
268. Serreze D. Control of autoimmune diabetes. Science. 2000;287:191a.
http://www.sciencemag.org/cgi/content/full/287/5451/191a
269. Atkinson M, Ellis T. Control of autoimmune diabetes. Science. 2000;287:191a.
http://www.sciencemag.org/cgi/content/full/287/5451/191a
270. Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, Michelsen B. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes. 1994 Dec;43(12):1478-84.
http://www.ncbi.nlm.nih.gov/pubmed/7958502
271. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med. 1996;183(4):1561-7.
http://www.ncbi.nlm.nih.gov/pubmed/8666914
272. Tian J, Clare-Salzler M, Herschenfeld A, Middleton B, Newman D, Mueller R, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice [see comments]. Nat Med. 1996;2(12):1348-53.
http://www.ncbi.nlm.nih.gov/pubmed/8946834
273. Ramiya VK, Shang XZ, Wasserfall CH, Maclaren NK. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoimmunity. 1997;26(3):139-51.
http://www.ncbi.nlm.nih.gov/pubmed/9550282
274. Han G, Li Y, Wang J, Wang R, Chen G, Song L, et al. Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD(500-585). J Immunol. 2005 Apr 15;174(8):4516-24.
http://www.ncbi.nlm.nih.gov/pubmed/15814672
275. Elliott JF, Qin HY, Bhatti S, Smith DK, Singh RK, Dillon T, et al. Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice. Diabetes. 1994 Dec;43(12):1494-9.
http://www.ncbi.nlm.nih.gov/pubmed/7525393
276. Bridgett M, Cetkovic-Cvrlje M, O'Rourke R, Shi Y, Narayanswami S, Lambert J, et al. Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic beta-cells. Diabetes. 1998;47(12):1848-56.
http://www.ncbi.nlm.nih.gov/pubmed/9836515
277. Geng L, Solimena M, Flavell RA, Sherwin RS, Hayday AC. Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease. Proc Natl Acad Sci U S A. 1998;95(17):10055-60.
http://www.ncbi.nlm.nih.gov/pubmed/9707599
278. Jasinski JM, Yu L, Nakayama M, Li MM, Lipes MA, Eisenbarth GS, et al. Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes. 2006 Jul;55(7):1978-84.
http://www.ncbi.nlm.nih.gov/pubmed/16804066
279. Kim SK, Tarbell KV, Sanna M, Vadeboncoeur M, Warganich T, Lee M, et al. Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14204-9.
http://www.ncbi.nlm.nih.gov/pubmed/15381770
280. Gebe JA, Unrath KA, Yue BB, Miyake T, Falk BA, Nepom GT. Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. J Autoimmun. 2008 Jun;30(4):197-206.
http://www.ncbi.nlm.nih.gov/pubmed/17949947
281. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1909-20.
http://www.ncbi.nlm.nih.gov/pubmed/18843118
282. Leslie RD, Atkinson MA, Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes. Diabetologia. 1999 Jan;42(1):3-14.
http://www.ncbi.nlm.nih.gov/pubmed/10027571
283. Andersen JN, Jansen PG, Echwald SM, Mortensen OH, Fukada T, Del Vecchio R, et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 2004 Jan;18(1):8-30.
http://www.ncbi.nlm.nih.gov/pubmed/14718383
284. Christie MR, Tun RY, Lo SS, Cassidy D, Brown TJ, Hollands J, et al. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes. 1992 Jul;41(7):782-7.
http://www.ncbi.nlm.nih.gov/pubmed/1612192
285. Hawkes CJ, Wasmeier C, Christie MR, Hutton JC. Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes. 1996;45(9):1187-92.
http://www.ncbi.nlm.nih.gov/pubmed/8772720
286. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol. 1995 Dec 1;155(11):5419-26.
http://www.ncbi.nlm.nih.gov/pubmed/7594559
287. Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes. 1998;47(5):733-42.
http://www.ncbi.nlm.nih.gov/pubmed/9588444
288. Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, Oles J, Hicks JM, et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol. 1994;152(6):3183-8.
http://www.ncbi.nlm.nih.gov/pubmed/8144912
289. Payton MA, Hawkes CJ, Christie MR. Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest. 1995;96(3):1506-11.
http://www.ncbi.nlm.nih.gov/pubmed/7657822
290. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, Maclaren NK, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A. 1996;93(6):2307-11.
http://www.ncbi.nlm.nih.gov/pubmed/8637868
291. Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Lai M, et al. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes. 1994 Oct;43(10):1254-9.
http://www.ncbi.nlm.nih.gov/pubmed/7926297
292. Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004 Feb;53(2):384-92.
http://www.ncbi.nlm.nih.gov/pubmed/14747289
293. Christie MR, Vohra G, Champagne P, Daneman D, Delovitch TL. Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J Exp Med. 1990 Sep 1;172(3):789-94.
http://www.ncbi.nlm.nih.gov/pubmed/2201748
294. Lan MS, Lu J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol. 1994;13(5):505-14.
http://www.ncbi.nlm.nih.gov/pubmed/8024693
295. Rabin DU, Pleasic SM, Palmer-Crocker R, Shapiro JA. Cloning and expression of IDDM-specific human autoantigens. Diabetes. 1992;41(2):183-6.
http://www.ncbi.nlm.nih.gov/pubmed/1733807
296. Wasmeier C, Hutton JC. Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem. 1996;271(30):18161-70.
http://www.ncbi.nlm.nih.gov/pubmed/8663434
297. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6367-70.
http://www.ncbi.nlm.nih.gov/pubmed/8692821
298. Smith PD, Barker KT, Wang J, Lu YJ, Shipley J, Crompton MR. ICAAR, a novel member of a new family of transmembrane, tyrosine phosphatase-like proteins. Biochem Biophys Res Commun. 1996 Dec 13;229(2):402-11.
http://www.ncbi.nlm.nih.gov/pubmed/8954911
299. Cui L, Yu WP, DeAizpurua HJ, Schmidli RS, Pallen CJ. Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes. J Biol Chem. 1996 Oct 4;271(40):24817-23.
http://www.ncbi.nlm.nih.gov/pubmed/8798755
300. Kawasaki E, Hutton JC, Eisenbarth GS. Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type 1 diabetes. Biochem Biophys Res Commun. 1996 Oct 14;227(2):440-7.
http://www.ncbi.nlm.nih.gov/pubmed/8878534
301. Li Q, Borovitskaya AE, DeSilva MG, Wasserfall C, Maclaren NK, Notkins AL, et al. Autoantigens in insulin-dependent diabetes mellitus: molecular cloning and characterization of human IA-2 beta. Proc Assoc Am Physicians. 1997 Jul;109(4):429-39.
http://www.ncbi.nlm.nih.gov/pubmed/9220540
302. Solimena M, Dirkx R, Jr., Hermel JM, Pleasic-Williams S, Shapiro JA, Caron L, et al. ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. Embo J. 1996;15(9):2102-14.
http://www.ncbi.nlm.nih.gov/pubmed/8641276
303. Diez J, Park Y, Zeller M, Brown D, Garza D, Ricordi C, et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes. 2001 Apr;50(4):895-900.
http://www.ncbi.nlm.nih.gov/pubmed/11289059
304. Genovese S, Bonfanti R, Bazzigaluppi E, Lampasona V, Benazzi E, Bosi E, et al. Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia. 1996 Oct;39(10):1223-6.
http://www.ncbi.nlm.nih.gov/pubmed/8897011
305. Bearzatto M, Naserke H, Piquer S, Koczwara K, Lampasona V, Williams A, et al. Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens. J Immunol. 2002 Apr 15;168(8):4202-8.
http://www.ncbi.nlm.nih.gov/pubmed/11937581
306. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol. 1996 Sep 15;157(6):2707-11.
http://www.ncbi.nlm.nih.gov/pubmed/8805677
307. Hermel JM, Dirkx R, Jr., Solimena M. Post-translational modifications of ICA512, a receptor tyrosine phosphatase-like protein of secretory granules. Eur J Neurosci. 1999 Aug;11(8):2609-20.
http://www.ncbi.nlm.nih.gov/pubmed/10457160
308. Ort T, Voronov S, Guo J, Zawalich K, Froehner SC, Zawalich W, et al. Dephosphorylation of beta2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. Embo J. 2001 Aug 1;20(15):4013-23.
http://www.ncbi.nlm.nih.gov/pubmed/11483505
309. Chiang MK, Flanagan JG. PTP-NP, a new member of the receptor protein tyrosine phosphatase family, implicated in development of nervous system and pancreatic endocrine cells. Development. 1996 Jul;122(7):2239-50.
http://www.ncbi.nlm.nih.gov/pubmed/8681804
310. Drake PG, Peters GH, Andersen HS, Hendriks W, Moller NP. A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2beta). Biochem J. 2003 Jul 15;373(Pt 2):393-401.
http://www.ncbi.nlm.nih.gov/pubmed/12697028
311. Ort T, Maksimova E, Dirkx R, Kachinsky AM, Berghs S, Froehner SC, et al. The receptor tyrosine phosphatase-like protein ICA512 binds the PDZ domains of beta2-syntrophin and nNOS in pancreatic beta-cells. Eur J Cell Biol. 2000 Sep;79(9):621-30.
http://www.ncbi.nlm.nih.gov/pubmed/11043403
312. Saeki K, Zhu M, Kubosaki A, Xie J, Lan MS, Notkins AL. Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes. 2002 Jun;51(6):1842-50.
http://www.ncbi.nlm.nih.gov/pubmed/12031972
313. Koczwara K, Schenker M, Schmid S, Kredel K, Ziegler AG, Bonifacio E. Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Clin Immunol. 2003 Feb;106(2):155-62.
http://www.ncbi.nlm.nih.gov/pubmed/12672406
314. Durinovic-Bello I, Hummel M, Ziegler AG. Cellular immune response to diverse islet cell antigens in IDDM. Diabetes. 1996;45(6):795-800.
http://www.ncbi.nlm.nih.gov/pubmed/8635655
315. Dotta F, Dionisi S, Viglietta V, Tiberti C, Matteoli MC, Cervoni M, et al. T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. Eur J Endocrinol. 1999 Sep;141(3):272-8.
http://www.ncbi.nlm.nih.gov/pubmed/10474125
316. Kelemen K, Crawford ML, Gill RG, Hutton JC, Wegmann D. Cellular immune response to phogrin in the NOD mouse: cloned T-cells cause destruction of islet transplants. Diabetes. 1999;48(8):1529-34.
http://www.ncbi.nlm.nih.gov/pubmed/10426369
317. Herzog BA, Ott PA, Dittrich MT, Quast S, Karulin AY, Kalbacher H, et al. Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects. J Autoimmun. 2004 Aug;23(1):45-54.
http://www.ncbi.nlm.nih.gov/pubmed/15236752
318. Muntasell A, Carrascal M, Alvarez I, Serradell L, van Veelen P, Verreck FA, et al. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J Immunol. 2004 Jul 15;173(2):1085-93.
http://www.ncbi.nlm.nih.gov/pubmed/15240697
319. Kelemen K, Wegmann DR, Hutton JC. T-cell epitope analysis on the autoantigen phogrin (IA-2beta) in the nonobese diabetic mouse. Diabetes. 2001 Aug;50(8):1729-34.
http://www.ncbi.nlm.nih.gov/pubmed/11473031
320. Achenbach P, Kelemen K, Wegmann DR, Hutton JC. Spontaneous peripheral T-cell responses to the IA-2beta (phogrin) autoantigen in young nonobese diabetic mice. J Autoimmun. 2002 Nov;19(3):111-6.
http://www.ncbi.nlm.nih.gov/pubmed/12419281
321. Kelemen K, Gottlieb PA, Putnam AL, Davidson HW, Wegmann DR, Hutton JC. HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes. J Immunol. 2004 Mar 15;172(6):3955-62.
http://www.ncbi.nlm.nih.gov/pubmed/15004204
322. Kudva YC, Deng YJ, Govindarajan R, Abraham RS, Marietta EV, Notkins AL, et al. HLA-DQ8 transgenic and NOD mice recognize different epitopes within the cytoplasmic region of the tyrosine phosphatase-like molecule, IA-2. Hum Immunol. 2001 Oct;62(10):1099-105.
http://www.ncbi.nlm.nih.gov/pubmed/11600216
323. Trembleau S, Penna G, Gregori S, Magistrelli G, Isacchi A, Adorini L. Early Th1 response in unprimed nonobese diabetic mice to the tyrosine phosphatase-like insulinoma-associated protein 2, an autoantigen in type 1 diabetes. J Immunol. 2000 Dec 15;165(12):6748-55.
http://www.ncbi.nlm.nih.gov/pubmed/11120794
324. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med. 1998 Apr;4(4):231-9.
http://www.ncbi.nlm.nih.gov/pubmed/9606176
325. Peakman M, Stevens EJ, Lohmann T, Narendran P, Dromey J, Alexander A, et al. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest. 1999 Nov;104(10):1449-57.
http://www.ncbi.nlm.nih.gov/pubmed/10562307
326. Lohmann T, Halder T, Engler J, Morgenthaler NG, Khoo-Morgenthaler UY, Schroder S, et al. T cell reactivity to DR*0401- and DQ*0302-binding peptides of the putative autoantigen IA-2 in type 1 diabetes. Exp Clin Endocrinol Diabetes. 1999;107(3):166-71.
http://www.ncbi.nlm.nih.gov/pubmed/10376440
327. Takahashi K, Honeyman MC, Harrison LC. Cytotoxic T cells to an epitope in the islet autoantigen IA-2 are not disease-specific. Clin Immunol. 2001 Jun;99(3):360-4.
http://www.ncbi.nlm.nih.gov/pubmed/11358432
328. Cai T, Krause MW, Odenwald WF, Toyama R, Notkins AL. The IA-2 gene family: homologs in Caenorhabditis elegans, Drosophila and zebrafish. Diabetologia. 2001 Jan;44(1):81-8.
http://www.ncbi.nlm.nih.gov/pubmed/11206415
329. Zahn TR, Macmorris MA, Dong W, Day R, Hutton JC. IDA-1, a Caenorhabditis elegans homolog of the diabetic autoantigens IA-2 and phogrin, is expressed in peptidergic neurons in the worm. J Comp Neurol. 2001 Jan 1;429(1):127-43.
http://www.ncbi.nlm.nih.gov/pubmed/11086294
330. Park YS, Kawasaki E, Kelemen K, Yu L, Schiller MR, Rewers M, et al. Humoral autoreactivity to an alternatively spliced variant of ICA512/IA-2 in Type I diabetes. Diabetologia. 2000 Oct;43(10):1293-301.
http://www.ncbi.nlm.nih.gov/pubmed/11079748
331. Pietropaolo M, Castano L, Babu S, Buelow R, Kuo YL, Martin S, et al. Islet cell autoantigen 69 kD (ICA69). Molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest. 1993 Jul;92(1):359-71.
http://www.ncbi.nlm.nih.gov/pubmed/8326004
332. Spitzenberger F, Pietropaolo S, Verkade P, Habermann B, Lacas-Gervais S, Mziaut H, et al. Islet cell autoantigen of 69 kDa is an arfaptin-related protein associated with the Golgi complex of insulinoma INS-1 cells. J Biol Chem. 2003 Jul 11;278(28):26166-73.
http://www.ncbi.nlm.nih.gov/pubmed/12682071
333. Mally MI, Cirulli V, Hayek A, Otonkoski T. ICA69 is expressed equally in the human endocrine and exocrine pancreas. Diabetologia. 1996 Apr;39(4):474-80.
http://www.ncbi.nlm.nih.gov/pubmed/8777998
334. Stassi G, Schloot N, Pietropaolo M. Islet cell autoantigen 69 kDa (ICA69) is preferentially expressed in the human islets of Langerhans than exocrine pancreas. Diabetologia. 1997 Jan;40(1):120-2.
http://www.ncbi.nlm.nih.gov/pubmed/9028728
335. Friday RP, Pietropaolo SL, Profozich J, Trucco M, Pietropaolo M. Alternative core promoters regulate tissue-specific transcription from the autoimmune diabetes-related ICA1 (ICA69) gene locus. J Biol Chem. 2003 Jan 10;278(2):853-63.
http://www.ncbi.nlm.nih.gov/pubmed/12409289
336. Mathews CE, Pietropaolo SL, Pietropaolo M. Reduced thymic expression of islet antigen contributes to loss of self-tolerance. Ann N Y Acad Sci. 2003 Nov;1005:412-7.
http://www.ncbi.nlm.nih.gov/pubmed/14679103
337. Winer S, Astsaturov I, Gaedigk R, Hammond-McKibben D, Pilon M, Song A, et al. ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide. J Immunol. 2002 Jan 1;168(1):475-82.
http://www.ncbi.nlm.nih.gov/pubmed/11751995
338. Roep BO, Duinkerken G, Schreuder GM, Kolb H, de Vries RR, Martin S. HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur J Immunol. 1996 Jun;26(6):1285-9.
http://www.ncbi.nlm.nih.gov/pubmed/8647206
339. Miyazaki I, Cheung RK, Gaedigk R, Hui MF, Van der Meulen J, Rajotte RV, et al. T cell activation and anergy to islet cell antigen in type I diabetes. J Immunol. 1995 Feb 1;154(3):1461-9.
http://www.ncbi.nlm.nih.gov/pubmed/7822811
340. Karges W, Hammond-McKibben D, Gaedigk R, Shibuya N, Cheung R, Dosch HM. Loss of self-tolerance to ICA69 in nonobese diabetic mice. Diabetes. 1997 Oct;46(10):1548-56.
http://www.ncbi.nlm.nih.gov/pubmed/9313748
341. Karjalainen J, Martin JM, Knip M, Ilonen J, Robinson BH, Savilahti E, et al. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med. 1992 Jul 30;327(5):302-7.
http://www.ncbi.nlm.nih.gov/pubmed/1377788
342. Norris J, Pietropaolo M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. J Endocrinol Invest. 1994 Jul-Aug;17(7):565-72.
http://www.ncbi.nlm.nih.gov/pubmed/7829831
343. Karlsson MG, Ludvigsson J. The ABBOS-peptide from bovine serum albumin causes an IFN-gamma and IL-4 mRNA response in lymphocytes from children with recent onset of type 1 diabetes. Diabetes Res Clin Pract. 2000 Mar;47(3):199-207.
http://www.ncbi.nlm.nih.gov/pubmed/10741569
344. Dosch H, Cheung RK, Karges W, Pietropaolo M, Becker DJ. Persistent T cell anergy in human type 1 diabetes. J Immunol. 1999 Dec 15;163(12):6933-40.
http://www.ncbi.nlm.nih.gov/pubmed/10586096
345. Steiner DF. The proprotein convertases. Curr Opin Chem Biol. 1998 Feb;2(1):31-9.
http://www.ncbi.nlm.nih.gov/pubmed/9667917
346. Davidson HW. (Pro)Insulin processing: a historical perspective. Cell Biochem Biophys. 2004;40(3 Suppl):143-58.
http://www.ncbi.nlm.nih.gov/pubmed/15289650
347. Davidson HW, Hutton JC. The insulin-secretory-granule carboxypeptidase H. Purification and demonstration of involvement in proinsulin processing. Biochem J. 1987 Jul 15;245(2):575-82.
http://www.ncbi.nlm.nih.gov/pubmed/2822027
348. Guest PC, Pipeleers D, Rossier J, Rhodes CJ, Hutton JC. Co-secretion of carboxypeptidase H and insulin from isolated rat islets of Langerhans. Biochem J. 1989 Dec 1;264(2):503-8.
http://www.ncbi.nlm.nih.gov/pubmed/2481446
349. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004 Aug;89(8):3629-43.
http://www.ncbi.nlm.nih.gov/pubmed/15292279
350. Betsholtz C, Svensson V, Rorsman F, Engstrom U, Westermark GT, Wilander E, et al. Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res. 1989 Aug;183(2):484-93.
http://www.ncbi.nlm.nih.gov/pubmed/2670595
351. Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF. An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem. 1988 Nov 25;263(33):17243-6.
http://www.ncbi.nlm.nih.gov/pubmed/3053705
352. Marzban L, Trigo-Gonzalez G, Zhu X, Rhodes CJ, Halban PA, Steiner DF, et al. Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes. 2004 Jan;53(1):141-8.
http://www.ncbi.nlm.nih.gov/pubmed/14693708
353. Panagiotopoulos C, Qin H, Tan R, Verchere CB. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes. 2003 Nov;52(11):2647-51.
http://www.ncbi.nlm.nih.gov/pubmed/14578281
354. Dallas-Pedretti A, McDuffie M, Haskins K. A diabetes-associated T-cell autoantigen maps to a telomeric locus on mouse chromosome 6. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1386-90.
http://www.ncbi.nlm.nih.gov/pubmed/7877988
355. Res P, Thole J, de Vries R. Heat-shock proteins and autoimmunity in humans. Springer Semin Immunopathol. 1991;13(1):81-98.
http://www.ncbi.nlm.nih.gov/pubmed/1776120
356. Brudzynski K, Martinez V. Synaptophysin-containing microvesicles transport heat-shock protein hsp60 in insulin-secreting beta cells. Cytotechnology. 1993;11(1):23-33.
http://www.ncbi.nlm.nih.gov/pubmed/7763633
357. Tsan MF, Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol. 2004 Apr;286(4):C739-44.
http://www.ncbi.nlm.nih.gov/pubmed/15001423
358. Panayi GS, Corrigall VM, Henderson B. Stress cytokines: pivotal proteins in immune regulatory networks; Opinion. Curr Opin Immunol. 2004 Aug;16(4):531-4.
http://www.ncbi.nlm.nih.gov/pubmed/15245751
359. Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1576-80.
http://www.ncbi.nlm.nih.gov/pubmed/2406723
360. Shimada A, Charlton B, Rohane P, Taylor-Edwards C, Fathman CG. Immune regulation in type 1 diabetes. J Autoimmun. 1996;9(2):263-9.
http://www.ncbi.nlm.nih.gov/pubmed/8738972
361. Elias D, Cohen IR. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes. 1995 Sep;44(9):1132-8.
http://www.ncbi.nlm.nih.gov/pubmed/7657040
362. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet. 1994 Mar 19;343(8899):704-6.
http://www.ncbi.nlm.nih.gov/pubmed/7907681
363. Bowman M, Atkinson MA. Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia. 2002 Sep;45(9):1350-1.
http://www.ncbi.nlm.nih.gov/pubmed/12242470
364. Ablamunits V, Elias D, Cohen IR. The pathogenicity of islet-infiltrating lymphocytes in the non-obese diabetic (NOD) mouse. Clin Exp Immunol. 1999 Feb;115(2):260-7.
http://www.ncbi.nlm.nih.gov/pubmed/9933451
365. Elias D, Cohen IR. The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin. Diabetes. 1996 Sep;45(9):1168-72.
http://www.ncbi.nlm.nih.gov/pubmed/8772717
366. Feili-Hariri M, Frantz MO, Morel PA. Prevention of diabetes in the NOD mouse by a Th1 clone specific for a hsp60 peptide. J Autoimmun. 2000 Mar;14(2):133-42.
http://www.ncbi.nlm.nih.gov/pubmed/10677244
367. Tikochinski Y, Elias D, Steeg C, Marcus H, Kantorowitz M, Reshef T, et al. A shared TCR CDR3 sequence in NOD mouse autoimmune diabetes. Int Immunol. 1999 Jun;11(6):951-6.
http://www.ncbi.nlm.nih.gov/pubmed/10360969
368. Dosch HM, Becker DJ. Measurement of T-cell autoreactivity in autoimmune diabetes. Diabetologia. 2000 Mar;43(3):386-7.
http://www.ncbi.nlm.nih.gov/pubmed/10768103
369. Kallmann BA, Lampeter EF, Hanifi-Moghaddam P, Hawa M, Leslie RD, Kolb H. Cytokine secretion patterns in twins discordant for Type I diabetes. Diabetologia. 1999 Sep;42(9):1080-5.
http://www.ncbi.nlm.nih.gov/pubmed/10447519
370. Abulafia-Lapid R, Gillis D, Yosef O, Atlan H, Cohen IR. T cells and autoantibodies to human HSP70 in type 1 diabetes in children. J Autoimmun. 2003 Jun;20(4):313-21.
http://www.ncbi.nlm.nih.gov/pubmed/12791317
371. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001 Nov 24;358(9295):1749-53.
http://www.ncbi.nlm.nih.gov/pubmed/11734230
372. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev. 2007 May;23(4):292-8.
http://www.ncbi.nlm.nih.gov/pubmed/17124720
373. Ebert DH, Bischof LJ, Streeper RS, Chapman SC, Svitek CA, Goldman JK, et al. Structure and promoter activity of an islet-specific glucose-6-phosphatase catalytic subunit-related gene. Diabetes. 1999 Mar;48(3):543-51.
http://www.ncbi.nlm.nih.gov/pubmed/10078554
374. Bischof LJ, Martin CC, Svitek CA, Stadelmaier BT, Hornbuckle LA, Goldman JK, et al. Characterization of the mouse islet-specific glucose-6-phosphatase catalytic subunit-related protein gene promoter by in situ footprinting: correlation with fusion gene expression in the islet-derived betaTC-3 and hamster insulinoma tumor cell lines. Diabetes. 2001 Mar;50(3):502-14.
http://www.ncbi.nlm.nih.gov/pubmed/11246869
375. Arden SD, Zahn T, Steegers S, Webb S, Bergman B, O'Brien RM, et al. Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. Diabetes. 1999 Mar;48(3):531-42.
http://www.ncbi.nlm.nih.gov/pubmed/10078553
376. Hutton JC, Eisenbarth GS. A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8626-8.
http://www.ncbi.nlm.nih.gov/pubmed/12861077
377. Shieh JJ, Pan CJ, Mansfield BC, Chou JY. The islet-specific glucose-6-phosphatase-related protein, implicated in diabetes, is a glycoprotein embedded in the endoplasmic reticulum membrane. FEBS Lett. 2004 Mar 26;562(1-3):160-4.
http://www.ncbi.nlm.nih.gov/pubmed/15044018
378. DiLorenzo TP, Graser RT, Ono T, Christianson GJ, Chapman HD, Roopenian DC, et al. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc Natl Acad Sci U S A. 1998;95(21):12538-43.
http://www.ncbi.nlm.nih.gov/pubmed/9770521
379. Verdaguer J, Yoon JW, Anderson B, Averill N, Utsugi T, Park BJ, et al. Acceleration of spontaneous diabetes in TCR-beta-transgenic nonobese diabetic mice by beta-cell cytotoxic CD8+ T cells expressing identical endogenous TCR-alpha chains. J Immunol. 1996 Nov 15;157(10):4726-35.
http://www.ncbi.nlm.nih.gov/pubmed/8906855
380. Verdaguer J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaria P. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J Exp Med. 1997 Nov 17;186(10):1663-76.
http://www.ncbi.nlm.nih.gov/pubmed/9362527
381. Tsai S, Shameli A, Santamaria P. CD8+ T cells in type 1 diabetes. Adv Immunol. 2008;100:79-124.
http://www.ncbi.nlm.nih.gov/pubmed/19111164
382. Anderson B, Park BJ, Verdaguer J, Amrani A, Santamaria P. Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9311-6.
http://www.ncbi.nlm.nih.gov/pubmed/10430939
383. Amrani A, Serra P, Yamanouchi J, Trudeau JD, Tan R, Elliott JF, et al. Expansion of the antigenic repertoire of a single T cell receptor upon T cell activation. J Immunol. 2001 Jul 15;167(2):655-66.
http://www.ncbi.nlm.nih.gov/pubmed/11441068
384. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest. 2003 Jan;111(2):217-23.
http://www.ncbi.nlm.nih.gov/pubmed/12531877
385. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes. 2004 Jun;53(6):1459-66.
http://www.ncbi.nlm.nih.gov/pubmed/15161749
386. Han B, Serra P, Yamanouchi J, Amrani A, Elliott JF, Dickie P, et al. Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest. 2005 Jul;115(7):1879-87.
http://www.ncbi.nlm.nih.gov/pubmed/15937548
387. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med. 2005 Jun;11(6):645-52.
http://www.ncbi.nlm.nih.gov/pubmed/15908957
388. Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol. 2008 Jun;127(3):359-65.
http://www.ncbi.nlm.nih.gov/pubmed/18358785
389. Gelber C, Paborsky L, Singer S, McAteer D, Tisch R, Jolicoeur C, et al. Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes. Diabetes. 1994 Jan;43(1):33-9.
http://www.ncbi.nlm.nih.gov/pubmed/8262314
390. Santamaria P, Utsugi T, Park BJ, Averill N, Kawazu S, Yoon JW. Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor alpha-chain CDR3 sequences. J Immunol. 1995 Mar 1;154(5):2494-503.
http://www.ncbi.nlm.nih.gov/pubmed/7868915
391. DiLorenzo TP, Lieberman SM, Takaki T, Honda S, Chapman HD, Santamaria P, et al. During the early prediabetic period in NOD mice, the pathogenic CD8(+) T-cell population comprises multiple antigenic specificities. Clin Immunol. 2002 Dec;105(3):332-41.
http://www.ncbi.nlm.nih.gov/pubmed/12498815
392. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab. 1996 Dec;81(12):4264-7.
http://www.ncbi.nlm.nih.gov/pubmed/8954025
393. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1983 Dec 23;222(4630):1337-9.
http://www.ncbi.nlm.nih.gov/pubmed/6362005
394. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol. 1990;8:647-79.
http://www.ncbi.nlm.nih.gov/pubmed/2188676
395. Wolfe T, Bot A, Hughes A, Mohrle U, Rodrigo E, Jaume JC, et al. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety. Eur J Immunol. 2002 Jan;32(1):113-21.
http://www.ncbi.nlm.nih.gov/pubmed/11754351
396. Greiner DL, Rossini AA, Mordes JP. Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: caveat emptor and primum non nocere. Clin Immunol. 2001 Aug;100(2):134-43.
http://www.ncbi.nlm.nih.gov/pubmed/11465941
397. Shimada A, Charlton B, Taylor-Edwards C, Fathman CG. Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes. 1996 Aug;45(8):1063-7.
http://www.ncbi.nlm.nih.gov/pubmed/8690153
398. Sreenan S, Pick AJ, Levisetti M, Baldwin AC, Pugh W, Polonsky KS. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes. 1999 May;48(5):989-96.
http://www.ncbi.nlm.nih.gov/pubmed/10331402
399. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 2006 Dec;55(12):3238-45.
http://www.ncbi.nlm.nih.gov/pubmed/17130466
400. Ott PA, Dittrich MT, Herzog BA, Guerkov R, Gottlieb PA, Putnam AL, et al. T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading. J Clin Immunol. 2004 Jul;24(4):327-39.
http://www.ncbi.nlm.nih.gov/pubmed/15163889
401. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003 May 29;423(6939):506-11.
http://www.ncbi.nlm.nih.gov/pubmed/12724780
402. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005 May;54(5):1415-22.
http://www.ncbi.nlm.nih.gov/pubmed/15855328
403. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med. 1989;169(5):1669-80.
http://www.ncbi.nlm.nih.gov/pubmed/2523954
404. Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med. 2005 Apr 18;201(8):1333-46.
http://www.ncbi.nlm.nih.gov/pubmed/15837817
405. Kolb H. Benign versus destructive insulitis. Diabetes Metab Rev. 1997 Sep;13(3):139-46.
http://www.ncbi.nlm.nih.gov/pubmed/9307887
406. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases [see comments]. Immunol Today. 1995;16(1):34-8.
http://www.ncbi.nlm.nih.gov/pubmed/7880387
407. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science. 1995;268(5214):1185-8.
http://www.ncbi.nlm.nih.gov/pubmed/7761837
408. Sarukhan A, Lanoue A, Franzke A, Brousse N, Buer J, von Boehmer H. Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model. Embo J. 1998;17(1):71-80.
http://www.ncbi.nlm.nih.gov/pubmed/9427742
409. Nagata S, Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449-56.
http://www.ncbi.nlm.nih.gov/pubmed/7533326
410. Jun HS, Santamaria P, Lim HW, Zhang ML, Yoon JW. Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice. Diabetes. 1999 Jan;48(1):34-42.
http://www.ncbi.nlm.nih.gov/pubmed/9892220
411. Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM. Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6688-93.
http://www.ncbi.nlm.nih.gov/pubmed/12750472
412. Eizirik DL, Mandrup-Poulsen T. A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia. 2001 Dec;44(12):2115-33.
http://www.ncbi.nlm.nih.gov/pubmed/11793013
413. Mandrup-Poulsen T. Beta cell death and protection. Ann N Y Acad Sci. 2003 Nov;1005:32-42.
http://www.ncbi.nlm.nih.gov/pubmed/14679038
414. Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol. 2004 Aug;4(4):403-7.
http://www.ncbi.nlm.nih.gov/pubmed/15251136
415. Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3434-8.
http://www.ncbi.nlm.nih.gov/pubmed/1565635
416. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18895-900.
http://www.ncbi.nlm.nih.gov/pubmed/19015530
417. Razavi R, Chan Y, Afifiyan FN, Liu XJ, Wan X, Yantha J, et al. TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell. 2006 Dec 15;127(6):1123-35.
http://www.ncbi.nlm.nih.gov/pubmed/17174891
418. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005 Jun 23;352(25):2598-608.
http://www.ncbi.nlm.nih.gov/pubmed/15972866
419. Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, et al. Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci. 2008 Dec;1150:152-6.
http://www.ncbi.nlm.nih.gov/pubmed/19120286
420. Faustman DL. Immunotherapy on trial for new-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1956-8.
http://www.ncbi.nlm.nih.gov/pubmed/18843119
421. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006 Nov 27;203(12):2737-47.
http://www.ncbi.nlm.nih.gov/pubmed/17116737
422. Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994 Jun 15;57(11):1537-43.
http://www.ncbi.nlm.nih.gov/pubmed/8009586
423. Herold KC, Taylor L. Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol Res. 2003;28(2):141-50.
http://www.ncbi.nlm.nih.gov/pubmed/14610290
424. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol. 1993 Feb;23(2):403-11.
http://www.ncbi.nlm.nih.gov/pubmed/8436176
425. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med. 2003 Sep;9(9):1202-8.
http://www.ncbi.nlm.nih.gov/pubmed/12937416
426. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13.
http://www.ncbi.nlm.nih.gov/pubmed/16167085
427. Karges B, Durinovic-Bello I, Heinze E, Debatin KM, Boehm B, Karges W. Immunological mechanisms associated with long-term remission of human type 1 diabetes. Diabetes Metab Res Rev. 2005 Oct 12.
http://www.ncbi.nlm.nih.gov/pubmed/16222648
428. Ogawa N, List JF, Habener JF, Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes. 2004 Jul;53(7):1700-5.
http://www.ncbi.nlm.nih.gov/pubmed/15220193
429. Mathis D, Vence L, Benoist C. beta-Cell death during progression to diabetes. Nature. 2001 Dec 13;414(6865):792-8.
http://www.ncbi.nlm.nih.gov/pubmed/11742411
430. Thomas HE, Kay TW. How beta cells die in type 1 diabetes. Curr Dir Autoimmun. 2001;4:144-70.
http://www.ncbi.nlm.nih.gov/pubmed/11569401
431. Signore A, Annovazzi A, Gradini R, Liddi R, Ruberti G. Fas and Fas ligand-mediated apoptosis and its role in autoimmune diabetes. Diabetes Metab Rev. 1998 Sep;14(3):197-206.
http://www.ncbi.nlm.nih.gov/pubmed/9816469
432. Savinov AY, Tcherepanov A, Green EA, Flavell RA, Chervonsky AV. Contribution of Fas to diabetes development. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):628-32.
http://www.ncbi.nlm.nih.gov/pubmed/12525697
433. Thomas HE, Darwiche R, Corbett JA, Kay TW. Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol. 1999 Aug 1;163(3):1562-9.
http://www.ncbi.nlm.nih.gov/pubmed/10415060
434. Amrani A, Verdaguer J, Anderson B, Utsugi T, Bou S, Santamaria P. Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest. 1999;103(8):1201-9.
http://www.ncbi.nlm.nih.gov/pubmed/10207172
435. Suarez-Pinzon WL, Mabley JG, Strynadka K, Power RF, Szabo C, Rabinovitch A. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice. J Autoimmun. 2001 Jun;16(4):449-55.
http://www.ncbi.nlm.nih.gov/pubmed/11437493
436. Kolb H, Kolb-Bachofen V. Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? Immunol Today. 1998 Dec;19(12):556-61.
http://www.ncbi.nlm.nih.gov/pubmed/9864946
437. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? [see comments]. Diabetes. 1994;43(5):613-21.
http://www.ncbi.nlm.nih.gov/pubmed/8168635
438. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003 Oct 15;66(8):1403-8.
http://www.ncbi.nlm.nih.gov/pubmed/14555214
439. O'Reilly LA, Hutchings PR, Crocker PR, Simpson E, Lund T, Kioussis D, et al. Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression. Eur J Immunol. 1991;21(5):1171-80.
http://www.ncbi.nlm.nih.gov/pubmed/1674689
440. Miller BJ, Appel MC, O'Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol. 1988;140(1):52-8.
http://www.ncbi.nlm.nih.gov/pubmed/3275717
441. Cooke A, Phillips JM, Parish NM. Tolerogenic strategies to halt or prevent type 1 diabetes. Nat Immunol. 2001 Sep;2(9):810-5.
http://www.ncbi.nlm.nih.gov/pubmed/11526391
442. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes. 1994 May;43(5):667-75.
http://www.ncbi.nlm.nih.gov/pubmed/8168644
443. Dilts SM, Solvason N, Lafferty KJ. The role of CD4 and CD8 T cells in the development of autoimmune diabetes. J Autoimmun. 1999 Nov;13(3):285-90.
http://www.ncbi.nlm.nih.gov/pubmed/10550215
444. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988 Apr 29;240(4852):659-62.
http://www.ncbi.nlm.nih.gov/pubmed/2966437
445. Wang B, Gonzalez A, Benoist C, Mathis D. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol. 1996;26(8):1762-9.
http://www.ncbi.nlm.nih.gov/pubmed/8765018
446. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383(6603):787-93.
http://www.ncbi.nlm.nih.gov/pubmed/8893001
447. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 1996;184(3):1093-9.
http://www.ncbi.nlm.nih.gov/pubmed/9064326
448. Wang B, Gonzalez A, Hoglund P, Katz JD, Benoist C, Mathis D. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes. 1998;47(8):1207-11.
http://www.ncbi.nlm.nih.gov/pubmed/9703318
449. Pakala SV, Kurrer MO, Katz JD. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med. 1997;186(2):299-306.
http://www.ncbi.nlm.nih.gov/pubmed/9221759
450. Poulin M, Haskins K. Induction of diabetes in nonobese diabetic mice by Th2 T cell clones from a TCR transgenic mouse. J Immunol. 2000;164(6):3072-8.
http://www.ncbi.nlm.nih.gov/pubmed/10706696
451. Wogensen L, Lee MS, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice. J Exp Med. 1994;179(4):1379-84.
http://www.ncbi.nlm.nih.gov/pubmed/8145050
452. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001 Sep;2(9):816-22.
http://www.ncbi.nlm.nih.gov/pubmed/11526392
453. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002 Jun;2(6):389-400.
http://www.ncbi.nlm.nih.gov/pubmed/12093005
454. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003 Mar;3(3):253-7.
http://www.ncbi.nlm.nih.gov/pubmed/12658273
455. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol. 2002 Dec 1;169(11):6210-7.
http://www.ncbi.nlm.nih.gov/pubmed/12444126
456. Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol. 2003 Oct;74(4):471-8.
http://www.ncbi.nlm.nih.gov/pubmed/14519757
457. van der Vliet HJ, Molling JW, von Blomberg BM, Nishi N, Kolgen W, van den Eertwegh AJ, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol. 2004 Jul;112(1):8-23.
http://www.ncbi.nlm.nih.gov/pubmed/15207777
458. Homann D, von Herrath M. Regulatory T cells and type 1 diabetes. Clin Immunol. 2004 Sep;112(3):202-9.
http://www.ncbi.nlm.nih.gov/pubmed/15308110
459. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol. 2003 Oct 15;171(8):4040-7.
http://www.ncbi.nlm.nih.gov/pubmed/14530324
460. Esteban LM, Tsoutsman T, Jordan MA, Roach D, Poulton LD, Brooks A, et al. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J Immunol. 2003 Sep 15;171(6):2873-8.
http://www.ncbi.nlm.nih.gov/pubmed/12960309
461. Berzins SP, Venanzi ES, Benoist C, Mathis D. T-cell compartments of prediabetic NOD mice. Diabetes. 2003 Feb;52(2):327-34.
http://www.ncbi.nlm.nih.gov/pubmed/12540604
462. Lee M, Koh JJ, Han SO, Ko KS, Ki SW. Prevention of autoimmune insulitis by delivery of interleukin-4 plasmid using a soluble and biodegradable polymeric carrier. Pharm Res. 2002 Mar;19(3):246-9.
http://www.ncbi.nlm.nih.gov/pubmed/11934229
463. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F. Thymic regulatory T cells. Autoimmun Rev. 2005 Nov;4(8):579-86.
http://www.ncbi.nlm.nih.gov/pubmed/16214099
464. You S, Slehoffer G, Barriot S, Bach JF, Chatenoud L. Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A. 2004 Aug 30.
http://www.ncbi.nlm.nih.gov/pubmed/15340148
465. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 2003 Nov;112(9):1310-2.
http://www.ncbi.nlm.nih.gov/pubmed/14597756
466. Strobel S. Oral tolerance, systemic immunoregulation, and autoimmunity. Ann N Y Acad Sci. 2002 Apr;958:47-58.
http://www.ncbi.nlm.nih.gov/pubmed/12021083
467. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001 Aug;182:207-14.
http://www.ncbi.nlm.nih.gov/pubmed/11722636
468. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001 Aug;182:68-79.
http://www.ncbi.nlm.nih.gov/pubmed/11722624
469. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003 May;18(5):605-17.
http://www.ncbi.nlm.nih.gov/pubmed/12753738
470. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002 Jul 15;196(2):247-53.
http://www.ncbi.nlm.nih.gov/pubmed/12119349
471. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity. 2003 Dec;19(6):877-89.
http://www.ncbi.nlm.nih.gov/pubmed/14670304
472. Feinberg MB, Silvestri G. T(S) cells and immune tolerance induction: a regulatory renaissance? Nat Immunol. 2002 Mar;3(3):215-7.
http://www.ncbi.nlm.nih.gov/pubmed/11875459
473. Chess L, Jiang H. Resurrecting CD8+ suppressor T cells. Nat Immunol. 2004 May;5(5):469-71.
http://www.ncbi.nlm.nih.gov/pubmed/15116110
474. Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, Yamagiwa S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol. 2004 Apr;16(2):135-43.
http://www.ncbi.nlm.nih.gov/pubmed/15036237
475. Antony PA, Restifo NP. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother. 2002 May-Jun;25(3):202-6.
http://www.ncbi.nlm.nih.gov/pubmed/12000861
476. Hammond KJ, Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr Opin Immunol. 2003 Dec;15(6):683-9.
http://www.ncbi.nlm.nih.gov/pubmed/14630203
477. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol. 2008 Mar 1;180(5):2863-75.
http://www.ncbi.nlm.nih.gov/pubmed/18292508
478. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179(3):973-84.
http://www.ncbi.nlm.nih.gov/pubmed/7509366
479. Quiniou-Debrie MC, Debray-Sachs M, Dardenne M, Czernichow P, Assan R, Bach JF. Anti-islet cellular and humoral immunity, T-cell subsets, and thymic function in type I diabetes. Diabetes. 1985;34(4):373-9.
http://www.ncbi.nlm.nih.gov/pubmed/3882501
480. Naik RG, Beckers C, Wentwoord R, Frenken A, Duinkerken G, Brooks-Worrell B, et al. Precursor frequencies of T-cells reactive to insulin in recent onset type 1 diabetes mellitus. J Autoimmun. 2004 Aug;23(1):55-61.
http://www.ncbi.nlm.nih.gov/pubmed/15236753
481. Roep BO, Atkinson MA, van Endert PM, Gottlieb PA, Wilson SB, Sachs JA. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. J Autoimmun. 1999;13(2):267-82.
http://www.ncbi.nlm.nih.gov/pubmed/10479395
482. Schloot NC, Meierhoff G, Karlsson Faresjo M, Ott P, Putnam A, Lehmann P, et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun. 2003 Dec;21(4):365-76.
http://www.ncbi.nlm.nih.gov/pubmed/14624759
483. Stratmann T, Martin-Orozco N, Mallet-Designe V, Poirot L, McGavern D, Losyev G, et al. Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J Clin Invest. 2003 Sep;112(6):902-14.
http://www.ncbi.nlm.nih.gov/pubmed/12975475
484. You S, Chen C, Lee WH, Wu CH, Judkowski V, Pinilla C, et al. Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides. J Immunol. 2003 Apr 15;170(8):4011-20.
http://www.ncbi.nlm.nih.gov/pubmed/12682229
485. Jang MH, Seth NP, Wucherpfennig KW. Ex vivo analysis of thymic CD4 T cells in nonobese diabetic mice with tetramers generated from I-A(g7)/class II-associated invariant chain peptide precursors. J Immunol. 2003 Oct 15;171(8):4175-86.
http://www.ncbi.nlm.nih.gov/pubmed/14530340
486. Liu CP, Jiang K, Wu CH, Lee WH, Lin WJ. Detection of glutamic acid decarboxylase-activated T cells with I-Ag7 tetramers. Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14596-601.
http://www.ncbi.nlm.nih.gov/pubmed/11106373
487. Mallone R, Nepom GT. MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin Immunol. 2004 Mar;110(3):232-42.
http://www.ncbi.nlm.nih.gov/pubmed/15047201